Comment from Merck & Co. Inc.

Summary: Merck & Co., Inc. supports the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program, noting that it successfully accelerates patient access through early structured engagement and rolling reviews without compromising regulatory rigor. The company argues that the program provides improved predictability for sponsors and demonstrates broad applicability for therapies with significant public health impacts.